



Moderna Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference

January 6, 2014

CAMBRIDGE, Mass., Jan. 6, 2014 —[Moderna Therapeutics](#), the pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the *in vivo* production of therapeutic proteins, announced today that President and founding Chief Executive Officer Stéphane Bancel will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference.

Bancel will focus on the potential of Moderna's mRNA therapeutics to transform drug development across a wide range of diseases and improve patients' lives.

The presentation will take place on Tuesday, January 14 at 8:30 a.m. PT in Elizabethan C/D at the Westin St. Francis Hotel in San Francisco.

For more information on Moderna Therapeutics please visit www.modernatx.com.

About Moderna Therapeutics

Moderna is pioneering [messenger RNA Therapeutics™](#), an entirely new *in vivo* drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 250 patent applications with more than 12,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.